Cigarettes Per Day
Introduction
Cigarettes per day (CPD) is a commonly used metric to quantify an individual's exposure to tobacco smoke. This measure provides an indication of smoking intensity and is a critical factor in understanding the health impacts associated with tobacco use. It serves as a foundational variable in epidemiological and genetic studies, helping researchers assess both direct and indirect effects of smoking on human health.
Biological Basis
Smoking behavior, including the number of cigarettes consumed daily, is influenced by a complex interplay of genetic and environmental factors. Genetic variations can impact an individual's susceptibility to nicotine addiction, metabolism of tobacco compounds, and the body's response to smoke exposure. For instance, genes within the Glutathione S-Transferase (GST) superfamily are of interest due to their role in metabolizing xenobiotics, such as those found in cigarette smoke. Variations in genes like GSTT1 and GSTM1 have been studied for their potential influence on lung function changes in response to smoking. [1]
In genome-wide association studies (GWAS), smoking status and measures like 'pack-years' (a cumulative measure of smoking exposure) or 'cigarettes per day' are frequently included as covariates. This is done to adjust for their significant influence on various phenotypes, demonstrating the pervasive biological impact of smoking. [1] These adjustments help researchers isolate genetic effects from the powerful environmental effect of smoking.
Clinical Relevance
The number of cigarettes smoked per day is a highly clinically relevant factor due to its strong association with numerous health conditions. It is a primary risk factor for chronic obstructive pulmonary disease (COPD) and significantly impacts lung function measures such as forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and forced expiratory flow between the 25th and 75th percentile (FEF25–75). [1] These lung function measures are crucial indicators of respiratory health, and their decline is directly linked to smoking intensity.
Clinically, CPD is used to assess an individual's risk for various diseases, guide smoking cessation interventions, and monitor the effectiveness of public health campaigns. In research, adjusting for smoking intensity is essential when studying other traits, such as C-reactive protein levels, liver enzymes, and metabolic traits, to ensure that observed associations are not confounded by tobacco exposure. [2]
Social Importance
From a societal perspective, 'cigarettes per day' has profound public health implications. High rates of smoking contribute significantly to disease burden, healthcare costs, and reduced quality of life globally. Understanding the genetic and environmental factors that influence smoking behavior and its intensity can inform public health strategies aimed at preventing smoking initiation, promoting cessation, and mitigating the adverse health effects of tobacco use. Genetic insights related to smoking may eventually help identify individuals at higher risk for addiction or specific smoking-related diseases, potentially leading to more personalized prevention and treatment approaches.
Methodological and Statistical Constraints
Many genome-wide association studies (GWAS) encounter limitations in sample size and statistical power, particularly when aiming to detect genetic effects that contribute modestly to phenotypic variation. For instance, some analyses had limited power to detect associations for single nucleotide polymorphisms (SNPs) explaining less than 4% of total phenotypic variation. [3] Furthermore, the use of earlier generation SNP arrays means that the genetic variation captured is only a subset of all common SNPs, potentially missing causal variants due to insufficient coverage of specific gene regions or an inability to comprehensively study candidate genes. [4]
Replication of genetic findings is crucial, but studies often encounter non-replication at the SNP level, even for variants within the same gene, possibly due to different underlying causal variants or variations in study design and statistical power. [5] The inherent challenge of multiple testing in GWAS necessitates stringent significance thresholds, which can increase the risk of false positives or obscure true associations with smaller effect sizes if not adequately powered. [4] Additionally, while imputation methods expand genomic coverage, they introduce potential error rates—estimated to range from 1.46% to 2.14% per allele—which can influence the reliability of inferred genotypes and subsequent association results. [6]
Phenotype Definition and Population Heterogeneity
The specific definition and measurement of smoking-related phenotypes, such as cigarettes per day, can vary across different research contexts, impacting the comparability and interpretability of findings. While studies often adjust for covariates like age, body mass index (BMI), height, pack-years, and smoking status, these adjustments may not fully capture the complexity of smoking behavior or its comprehensive biological effects. [1] Phenotypes might be based on single measurements, means of multiple observations over time, or rates of change, each introducing different statistical properties and potential for measurement variability. [1] Residual confounding from such covariates could obscure true genetic associations or lead to spurious findings.
Genetic associations can be population-specific, meaning findings from one cohort may not fully generalize to populations with different ancestries or environmental exposures. Studies often focus on specific populations, such as those of European descent, thereby limiting the transferability of results to more diverse groups. [7] Furthermore, some analyses might pool sexes without performing sex-specific analyses, potentially missing SNPs that are associated with a phenotype only in females or males. [4] While certain family-based association tests are robust to population admixture, residual stratification effects, though often minimal, can still influence results. [8]
Environmental Interactions and Remaining Knowledge Gaps
Genetic variants may influence phenotypes in a context-specific manner, with their effects significantly modulated by environmental influences that are not always comprehensively captured or investigated in studies. [3] For instance, the impact of genetic factors on smoking behavior or its related health outcomes could be substantially altered by dietary habits, occupational exposures, or other lifestyle factors, representing a significant source of uninvestigated variability. Current research often does not undertake investigations of gene-environmental interactions, leaving a substantial gap in understanding the full etiology of complex traits. [3]
Despite extensive covariate adjustments, unmeasured or residual confounders, such as socioeconomic status, specific dietary patterns, or other health behaviors, can still influence observed genetic associations. These unaccounted factors, alongside complex gene-gene interactions, contribute to the phenomenon of "missing heritability," where identified genetic variants explain only a fraction of the total phenotypic variation. [9] Fully elucidating the genetic and environmental architecture of complex traits like cigarettes per day requires larger, more diverse cohorts and advanced analytical methods to uncover these intricate relationships and reduce remaining knowledge gaps. [9]
Variants
Genetic variations play a significant role in influencing an individual's smoking behavior, including the number of cigarettes consumed per day, and the associated health risks. These variants can affect how the body processes nicotine, how the brain responds to it, and an individual's susceptibility to smoking-related diseases. Understanding these genetic underpinnings helps to explain the diverse responses to nicotine and the varying levels of addiction.
Genes encoding nicotinic acetylcholine receptor subunits, such as CHRNA3, CHRNA5, and CHRNB4, play a crucial role in nicotine dependence and smoking behavior. These receptors are ligand-gated ion channels found in the brain and other tissues, where they bind to acetylcholine and nicotine, mediating neurotransmission. Genome-wide association studies have been instrumental in identifying genetic variants associated with complex human traits, including behaviors and physiological responses. [10] Variants within the CHRNA3-CHRNA5-CHRNB4 gene cluster, including rs542137493, rs11637630, rs1051730 in CHRNA3; rs16969968, rs76474922, rs2229961 in CHRNA5; and rs12902602, rs547290720, rs141208602 in CHRNB4, have been extensively studied for their impact on the brain's response to nicotine. Specific alleles can influence receptor sensitivity, density, or function, thereby affecting the rewarding effects of nicotine, the severity of withdrawal symptoms, and an individual's propensity to smoke more cigarettes per day. These genetic differences contribute significantly to the heritability of smoking quantity and the likelihood of successful smoking cessation, highlighting the complex interplay between genetics and environmental factors in addiction. [9]
The cytochrome P450 2A6 enzyme, encoded by the CYP2A6 gene, is the primary enzyme responsible for metabolizing nicotine into cotinine in the liver, a critical step in its elimination from the body. Genetic variations in CYP2A6, such as rs56113850, rs28399442, and rs55921593, significantly influence the rate at which individuals metabolize nicotine, a process that can be explored through genome-wide association studies of various biological pathways . Slower nicotine metabolism, often due to certain CYP2A6 variants, can lead to higher and longer-lasting nicotine levels in the bloodstream, which may reduce the number of cigarettes an individual needs to smoke to achieve desired effects, thus impacting cigarettes per day. Conversely, rapid metabolizers might smoke more to maintain nicotine levels. The CYP2A7 gene, located near CYP2A6 on chromosome 19, is often considered in conjunction with CYP2A6 due to its sequence similarity, though it is generally expressed at very low levels or considered a pseudogene, with variants like rs117824460, rs7247098, and rs79468636 potentially influencing the overall metabolic capacity or regulatory landscape of the CYP2A gene cluster. These genetic factors contribute to individual differences in drug response and overall health outcomes. [6]
Other genetic loci also contribute to the complex landscape of smoking behavior and its health consequences. HYKK (hypothetical kinase) is a less characterized gene, but its variants, including rs11852372, rs10519203, and rs8034191, might play roles in cellular signaling pathways that indirectly affect neuronal function or stress responses relevant to addiction. The CRABP1 (cellular retinoic acid binding protein 1) and IREB2 (iron responsive element binding protein 2) genes, with variants such as rs72736802, rs143127868, and rs2869037, are involved in cellular processes like retinoid metabolism and iron homeostasis, respectively, both of which can be impacted by chronic smoking and influence overall cellular health. PSMA4 (proteasome 20S subunit alpha 4), with variants like rs59133824, rs59683676, and rs1052035, encodes a component of the proteasome, a protein complex essential for protein degradation and cellular quality control, processes often perturbed by the oxidative stress induced by cigarette smoke. Finally, the ADAMTS7 (ADAM metallopeptidase with thrombospondin type 1 motif 7) gene, including variants rs4886589, rs567139777, rs2277549, and those within the GOLGA6GP-ADAMTS7 region like rs28673808 and rs12906847, is recognized for its associations with cardiovascular health, a major concern for smokers. These variants may influence arterial plaque formation and inflammation, thereby modulating the risk of smoking-related cardiovascular diseases and potentially influencing an individual's overall health trajectory, which can impact lifestyle choices like smoking quantity . [11], [12]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs11852372 rs10519203 rs8034191 |
HYKK | forced expiratory volume, response to bronchodilator FEV/FVC ratio, response to bronchodilator emphysema pattern measurement lung cancer cigarettes per day measurement |
| rs72736802 rs143127868 rs2869037 |
CRABP1 - IREB2 | FEV/FVC ratio, response to bronchodilator forced expiratory volume, response to bronchodilator cigarettes per day measurement |
| rs59133824 rs59683676 rs1052035 |
PSMA4 | forced expiratory volume, response to bronchodilator FEV/FVC ratio, response to bronchodilator cigarettes per day measurement |
| rs12902602 rs547290720 rs141208602 |
CHRNB4 | forced expiratory volume, response to bronchodilator FEV/FVC ratio, response to bronchodilator smoking behavior, body mass index body mass index cigarettes per day measurement |
| rs56113850 rs28399442 rs55921593 |
CYP2A6 | nicotine metabolite ratio forced expiratory volume, response to bronchodilator caffeine metabolite measurement cigarettes per day measurement tobacco smoke exposure measurement |
| rs542137493 rs11637630 rs1051730 |
CHRNA3 | cigarettes per day measurement smoking cessation |
| rs4886589 rs567139777 rs2277549 |
ADAMTS7 | cigarettes per day measurement |
| rs16969968 rs76474922 rs2229961 |
CHRNA5 | forced expiratory volume FEV/FVC ratio forced expiratory volume, response to bronchodilator FEV/FVC ratio, response to bronchodilator cigarettes per day measurement |
| rs28673808 rs12906847 |
GOLGA6GP - ADAMTS7 | cigarettes per day measurement smoking cessation |
| rs117824460 rs7247098 rs79468636 |
CYP2A6 - CYP2A7 | alkaline phosphatase measurement cigarettes per day measurement smoking cessation serum albumin amount C-reactive protein measurement |
Defining and Measuring Cigarette Consumption
The trait 'cigarettes per day' serves as a fundamental quantitative measure of an individual's daily tobacco exposure. This precise operational definition directly quantifies the intensity of a smoking habit, allowing for a continuous spectrum of consumption rather than mere categorical assignment. [13] Researchers commonly ascertain this measure through self-report, where participants estimate their average daily cigarette intake, providing a direct numerical value crucial for various epidemiological and genetic investigations. [13] Such a precise measurement approach is essential for understanding dose-response relationships and the varying impacts of tobacco on health.
This quantitative metric is frequently employed in scientific studies as a key covariate. By adjusting for 'cigarettes per day' in statistical models, researchers can account for its potential confounding effects on diverse health outcomes, thereby enabling a more accurate isolation of underlying genetic influences. [13] This approach helps to refine associations between genetic markers and traits like subclinical atherosclerosis, ensuring that observed relationships are independent of the immediate impact of smoking intensity. [13]
Classification of Smoking Exposure
While 'cigarettes per day' provides a continuous, dimensional assessment of smoking, it is also integrated within broader categorical classification systems to define an individual's overall smoking status. These widely recognized categories include "current smoking" (yes/no), "former smoking" (yes/no), and "never smoking," which are crucial for initial population stratification in large-scale studies. [1] These classifications provide a simplified yet robust framework for grouping individuals based on their historical and present tobacco use patterns.
Further extending the classification of smoking exposure, the concept of "pack-years" offers a cumulative measure that combines both the intensity and duration of smoking. Calculated by multiplying the number of packs smoked per day by the total years of smoking, "pack-years" provides a comprehensive assessment of lifetime tobacco exposure, particularly relevant for chronic conditions like pulmonary diseases. [1] This metric is frequently adjusted for in analyses alongside "current smoking" status and 'cigarettes per day' to capture the multifaceted nature of tobacco's influence on health. [1]
Terminology and Clinical Significance
The terminology surrounding 'cigarettes per day' is straightforward and universally understood within medical and public health communities, directly communicating the rate of an individual's cigarette consumption. Key terms like "smoking status" and "pack-years" complement 'cigarettes per day' by providing broader categorical and cumulative measures of tobacco exposure, respectively. [1] This standardized vocabulary ensures consistent reporting and interpretation of tobacco use patterns across diverse research and clinical contexts.
The clinical and scientific significance of 'cigarettes per day' is substantial, as it is a critical variable for assessing disease risk and progression. High daily cigarette consumption is consistently associated with increased risk for a myriad of health issues, including cardiovascular disease, pulmonary dysfunction, and metabolic disturbances. [13] Including 'cigarettes per day' in statistical adjustments helps researchers distinguish between genetic predispositions and environmental exposures, thereby enhancing the precision of risk assessment and informing targeted public health strategies. [13]
Biological Background
Cigarettes per day, a measure of an individual's smoking habit, profoundly impacts human biology at multiple levels, from molecular pathways to systemic organ function. The complex mixture of chemicals in cigarette smoke interacts with various biological systems, leading to disruptions in normal physiological processes and contributing to the development of numerous diseases. Understanding these interactions involves examining how genes influence susceptibility, how cellular functions are altered, and the broad pathophysiological consequences across different tissues and organs.
Pulmonary Function and Detoxification Pathways
The respiratory system is the primary point of contact for cigarette smoke, leading to direct and severe consequences for lung function. Exposure to smoke damages lung tissue, affecting key measures such as forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and forced expiratory flow (FEF25–75), which are critical indicators of pulmonary health. [1] Conditions like chronic bronchitis, emphysema, and chronic obstructive pulmonary disease (COPD) are directly linked to smoking, reflecting a breakdown in the structural integrity and functional capacity of the lungs. [1] These pathophysiological processes involve chronic inflammation and structural remodeling of the airways and alveoli, impairing gas exchange and leading to respiratory distress.
At the cellular and molecular level, the body attempts to metabolize the xenobiotics (foreign chemical compounds) present in cigarette smoke. The Glutathione S-Transferase (GST) superfamily of enzymes plays a crucial role in this detoxification process. [1] Genetic variations within GST genes, such as GSTP1, GSTM1, and GSTT1, are of significant interest because they can influence an individual's capacity to detoxify harmful compounds. [1] For instance, deletions in GSTT1 alone or in combination with GSTM1 deletions have been observed to impact the annual change in lung function measures in population-based cohorts. [1] This highlights how genetic differences in metabolic enzymes can modulate the body's response to cigarette smoke and contribute to varying degrees of lung damage.
Metabolic Regulation and Systemic Inflammation
Smoking significantly impacts systemic metabolic processes and inflammatory responses, contributing to a range of health issues beyond the lungs. Plasma C-reactive protein (CRP), a key biomarker of systemic inflammation, is consistently associated with various metabolic and cardiovascular diseases. [14] Studies have identified genetic loci related to metabolic-syndrome pathways, including genes like LEPR, HNF1A, IL6R, and GCKR, which associate with plasma CRP levels. [2] Specifically, polymorphisms in the HNF1A gene, which encodes a hepatocyte nuclear factor, have been linked to C-reactive protein concentrations, underscoring the genetic influence on systemic inflammatory markers. [14]
Beyond inflammation, smoking can disrupt broader metabolic homeostasis, affecting parameters such as plasma levels of liver enzymes, fasting glucose, insulin, and lipid profiles. [15] These disruptions contribute to metabolic traits that are often adjusted for in genetic studies, including body mass index (BMI), which has a strong effect on these traits. [5] Furthermore, the GLUT9 gene has been associated with serum uric acid levels, which in turn are linked to the risk of gout, demonstrating how specific genetic mechanisms can influence metabolic byproducts that are also affected by lifestyle factors like smoking. [16] These interconnected molecular and cellular pathways, involving critical proteins, enzymes, and regulatory networks, collectively contribute to the systemic metabolic burden imposed by smoking.
Genetic Influences on Smoking-Related Traits
Genetic mechanisms play a substantial role in mediating an individual's susceptibility to the effects of smoking and in influencing related health outcomes. Genome-wide association studies (GWAS) often employ additive genetic models to test the association between single nucleotide polymorphisms (SNPs) and various traits, assuming an effect per copy of a minor allele. [11] These studies frequently adjust for smoking status, pack-years, and sustained smoking to isolate genetic effects from environmental factors. [1] For instance, the CHI3L1 gene, which encodes the protein YKL-40, has been found to have variations that affect serum YKL-40 levels, the risk of asthma, and overall lung function. [17] Such genetic predispositions can modify how an individual's respiratory system responds to chronic smoke exposure.
Beyond respiratory function, genetic variants also influence other systemic markers and biomolecules. The ABO histo-blood group antigen, determined by specific genetic loci, has been associated with soluble Intercellular Adhesion Molecule 1 (ICAM-1), a key molecule involved in inflammatory and immune responses. [7] Similarly, variants in genes like TF and HFE significantly explain a portion of the genetic variation in serum-transferrin levels, affecting iron metabolism. [8] These findings illustrate how diverse genetic mechanisms, from gene functions to regulatory elements, contribute to the complex interplay between an individual's genetic makeup and their physiological responses to environmental factors like cigarette smoking.
Broader Physiological Consequences
The systemic consequences of cigarette smoking extend to critical physiological systems, notably affecting cardiovascular health and blood composition. Chronic smoking is a well-established risk factor for cardiovascular disease, contributing to processes like atherosclerosis, the hardening and narrowing of arteries. [13] At a molecular level, smoking impacts hemostatic factors, such as fibrinogen levels, which are routinely adjusted for current cigarette use in studies. [4] Elevated fibrinogen can contribute to increased blood viscosity and a pro-thrombotic state, increasing the risk of cardiovascular events.
Furthermore, smoking perturbs lipid metabolism, a crucial aspect of cardiovascular health. Individuals' lipid profiles, including levels of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides, are significantly influenced by smoking. [9] Studies often account for lipid-lowering therapy and other metabolic covariates like BMI, age, and sex to understand the independent effects of smoking on these markers. [9] The cumulative effect of these disruptions, impacting key biomolecules and cellular functions across multiple organ systems, underscores the pervasive and detrimental impact of cigarette smoking on overall human health.
Xenobiotic Metabolism and Detoxification
The body employs specific metabolic pathways to process and eliminate foreign compounds, known as xenobiotics, which include harmful substances present in cigarette smoke. The Glutathione S-Transferase (GST) superfamily of genes plays a critical role in this detoxification process. Enzymes such as those encoded by _GSTP1_, _GSTM1_, and _GSTT1_ facilitate the metabolism of these compounds, converting them into more excretable forms.. [1] Variations in these genes, such as deletions in _GSTT1_ alone or in combination with _GSTM1_ deletions, have been observed to influence lung function measures. This suggests that the efficiency of these metabolic pathways is a crucial determinant in an individual's susceptibility to the adverse effects of cigarette smoke, impacting long-term pulmonary health and potentially contributing to conditions like chronic obstructive pulmonary disease (COPD).
Systemic Inflammation and Immune Modulation
Cigarette smoking status is a significant factor that can influence systemic inflammation throughout the body. Plasma C-reactive protein (CRP) serves as a widely recognized marker of this systemic inflammatory state.. [2] Genetic loci related to metabolic-syndrome pathways, including the _IL6R_ gene which encodes a component of the interleukin-6 receptor, are associated with plasma CRP levels.. [2] This indicates that smoking can contribute to a broader inflammatory response, which is an integrated physiological process. This pathway crosstalk, potentially modulated by genetic predispositions, highlights how smoking can lead to emergent properties such as chronic systemic inflammation, affecting various metabolic traits and increasing disease risks.. [18]
Lipid and Carbohydrate Metabolism
Genetic variants can profoundly influence the homeostasis of essential endogenous metabolites, including key lipids, carbohydrates, and amino acids, thereby providing a functional readout of the body's physiological state.. [11] Genes such as _LEPR_, _HNF1A_, and _GCKR_ are implicated in metabolic-syndrome pathways, affecting the regulation of energy metabolism. Furthermore, the enzymatic activities of genes like _FADS1_ and _LIPC_ are strongly associated with genetically determined metabolic profiles, influencing the balance of various metabolic intermediates.. [11] Dysregulation within these intricate metabolic pathways, possibly exacerbated by factors like smoking, can lead to altered metabolic phenotypes, contributing to conditions such as dyslipidemia and metabolic syndrome, which represent significant disease-relevant mechanisms.
Pulmonary Tissue Homeostasis and Disease Progression
Lung function measures are directly impacted by environmental exposures like cigarette smoking, and specific genetic variations can modify these outcomes. For instance, variations within the _CHI3L1_ gene have been shown to exert effects on lung function and influence the risk of asthma.. [17] These mechanisms are vital for maintaining the structural integrity and functional capacity of pulmonary tissues. Their dysregulation, often a result of chronic exposure to cigarette smoke combined with individual genetic susceptibility, can contribute to the initiation and progression of respiratory diseases. The interplay between environmental factors and genetic predispositions highlights crucial compensatory mechanisms and potential therapeutic targets for complex pulmonary disorders.
Risk Stratification and Prognostic Implications
The number of cigarettes consumed daily serves as a critical parameter in clinical risk stratification, enabling the identification of individuals at a significantly elevated risk for a spectrum of chronic diseases. Research consistently incorporates smoking status and intensity, such as 'cigarettes per day' or pack-years, as essential covariates when assessing disease risk, highlighting its independent prognostic value in predicting adverse health outcomes. [13] For instance, the quantity of cigarettes smoked daily is a key factor in multivariate models designed to predict subclinical atherosclerosis, specifically maximum carotid artery intima-media thickness, which is a well-established predictor of future cardiovascular events. [13] This detailed understanding of smoking habits is indispensable for personalizing prevention strategies and initiating early, targeted interventions, particularly for patients presenting with additional risk factors.
Impact on Physiological Systems and Biomarker Profiles
The daily consumption of cigarettes profoundly influences multiple physiological systems and significantly alters key biomarker profiles, reflecting its pervasive association with numerous comorbidities. Lung function, a primary target of inhaled smoke, demonstrates dose-dependent adverse effects, with measures like forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) showing declines that are adjusted for current or former smoking status and pack-years. [1] Furthermore, smoking contributes to systemic inflammation, as evidenced by the necessary adjustment for smoking status in studies of C-reactive protein, and impacts lipid metabolism, with current smokers exhibiting distinct lipoprotein(a) levels. [17] These widespread associations underscore 'cigarettes per day' as a critical factor influencing diverse disease pathways, from pulmonary damage, partially mediated by xenobiotic metabolism through genes like Glutathione S-Transferase, to increased cardiovascular disease risk. [1]
Guiding Clinical Assessment and Intervention Strategies
A precise understanding of a patient's 'cigarettes per day' is foundational for comprehensive clinical assessment, directly informing diagnostic utility, treatment selection, and monitoring strategies. Given its profound and multifaceted impact on health, a detailed smoking history, encompassing both duration and intensity, empowers clinicians to accurately interpret symptoms, effectively stratify patients for specific conditions, and select the most appropriate diagnostic tests. [13] For example, the interpretation of lung function tests is critically influenced by a patient's smoking history, and genetic studies suggest that analyses stratified by smoking status can reveal unique and important genetic associations. [1] This vital information is also paramount for guiding therapeutic decisions, meticulously monitoring disease progression, and, most critically, implementing robust primary and secondary prevention strategies focused on smoking cessation to mitigate future health complications.
References
[1] Wilk, J. B., et al. "Framingham Heart Study genome-wide association: results for pulmonary function measures." BMC Medical Genetics, vol. 8, no. S1, 2007, p. S8.
[2] Ridker, P. M., et al. "Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study." The American Journal of Human Genetics, vol. 82, no. 5, 2008, pp. 1185–1192.
[3] Vasan, R. S., et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Medical Genetics, vol. 8, no. S1, 2007, S4.
[4] Yang, Q. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Med Genet, vol. 8, suppl. 1, 2007, p. S7.
[5] Sabatti, C. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nat Genet, vol. 40, no. 12, 2008, pp. 1396-1403.
[6] Willer, CJ. "Newly identified loci that influence lipid concentrations and risk of coronary artery disease." Nat Genet, vol. 40, no. 2, 2008, pp. 161-169.
[7] Pare, G. "Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women." PLoS Genet, vol. 4, no. 7, 2008, p. e1000118.
[8] Benyamin, B. "Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels." Am J Hum Genet, vol. 84, no. 1, 2009, pp. 60-65.
[9] Kathiresan, S. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nat Genet, vol. 40, no. 12, 2008, pp. 1428-1437.
[10] Benjamin, Emelia J., et al. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Medical Genetics, vol. 8, no. Suppl 1, 2007, p. S11.
[11] Gieger, C., et al. "Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum." PLoS Genetics, vol. 4, no. 11, November 2008, e1000282.
[12] Wallace, Cathryn, et al. "Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia." American Journal of Human Genetics, vol. 82, no. 1, 2008, pp. 139-149.
[13] O'Donnell, Christopher J., et al. "Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study." BMC Medical Genetics, vol. 8, no. S1, 2007, p. S3.
[14] Reiner, Alexander P., et al. "Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein." The American Journal of Human Genetics, vol. 82, no. 5, 2008, pp. 1193-1201.
[15] Yuan, X., et al. "Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes." The American Journal of Human Genetics, vol. 83, no. 4, 2008, pp. 520–528.
[16] Dehghan, A., et al. "Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study." The Lancet, vol. 372, no. 9654, 2008, pp. 1823-1831.
[17] Ober, C., et al. "Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function." The New England Journal of Medicine, vol. 358, no. 16, 17 Apr. 2008, pp. 1682–1691.
[18] Walter, R. E., et al. "Systemic inflammation and COPD: The Framingham Heart Study." Chest, in press.